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Abstract 
Given the difference in incidence of biologic subtype of breast cancer between black and white women, and the 
potential disparity in type of surgery in black and white women presenting with early stage breast cancer, this study 
aimed to examine the odds of mastectomy compared to lumpectomy by molecular subtype in black and white 
women with size T1 and T2 invasive breast cancer. Using the SEER database, breast operation choice for women over 
the age of 15 with T1 or T2 tumors between 2010 and 2012 were examined. Tumors were categorized according to 
the Breast Subtype variable in the SEER database and data were stratified by tumor size and race. Bivariate compari-
sons and logistic regression models adjusted for age were used. In women with T1 or T2 tumors, mastectomy rates 
were higher in women with Her2 positive tumors than in those with Her2 negative tumors. When Her2 results are the 
same among comparison groups, those women with HR positive tumors were less likely to undergo a mastectomy 
than those with HR negative tumors. In T1 tumors, the magnitude of the association was larger for white women than 
women of other races. Results suggest there are differences in surgical decision making based on breast cancer sub-
type in women with T1 or T2 tumors and that race may play a role for size T1 tumors. The strong association between 
Her2 positive tumors and higher mastectomy rates warrants further investigation.
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Background
Breast cancer is a heterogeneous malignancy which has 
been classified by gene-expression profiling into distinct 
molecular subtypes that provide important prognos-
tic and predictive information (Perou et  al. 2000; Sorlie 
et al. 2001). Estrogen receptor (ER), progesterone recep-
tor (PR) and human epidermal growth factor receptor-2 
(Her2) represent the elements that define these breast 
cancer subtypes and are routinely obtained to guide sys-
temic therapy decision making. Marked differences have 
been noted in long-term breast cancer related outcomes 
according to disease subtype, including significantly 
worse recurrence rates and overall survival in those 
patients with Her2 positive tumors and tumors that lack 
expression of ER, PR and Her2 (triple negative) (Sorlie 
et  al. 2001, 2003; Carey et  al. 2006; Slamon et  al. 1987; 
Ravidn and Chamness 1995). Equivalent disease-free and 
overall survival for breast-conserving surgery—lumpec-
tomy followed by radiotherapy—and mastectomy has 
been well described in multiple, large, randomized con-
trolled trials (Fisher et  al. 2002; Veronesi et  al. 2002). 
These trials were performed prior to the implementation 
of biological subtype differentiation; therefore, no dif-
ferences in outcome based on type of surgical treatment 
received according to subtype can be ascertained from 
these studies. In the modern era, there have been dis-
cordant findings regarding locoregional recurrence rates 
between subtypes. While it would be logical to question 
the use of breast-conserving surgery in those patients 
with more aggressive tumor biology in the triple nega-
tive or Her2 positive cohorts, multiple studies have dem-
onstrated no significant difference in LRR related to the 
subtypes (Freedman et al. 2009; Haffty et al. 2006; Peter-
son et al. 2014; Gangi et al. 2014). There is no current evi-
dence to suggest that the surgical management of early 
stage breast cancer should differ based on tumor subtype.
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In the United States, there are documented differences 
in the racial distribution of biologic subtype, type of sur-
gery, and treatment outcomes for breast cancer. White 
women present with the highest incidence of ER/PR 
positive/Her2 negative tumors while black women have 
the highest incidence of triple negative tumors (Amend 
et  al. 2006; Howlader et  al. 2014). Five year survival is 
lower for black women compared to white women across 
subtypes (Chen et al. 2014), and there is a demonstrated 
difference in disease free survival by race and molecular 
subtype (Sparano et  al. 2012). There is some evidence 
that black women are more likely to undergo mastectomy 
compared to white women; however, it is unclear if this 
is due to later stage at time of diagnosis (Sparano et  al. 
2012; Dookeran et al. 2015).
A recent analysis of SEER data found that women with 
Her2 positive disease, regardless of hormone receptor 
positivity, have higher odds of mastectomy compared to 
those who are Her2 negative/HR positive. Women with 
triple negative breast cancer also had higher odds of 
mastectomy compared to the Her2 negative/HR posi-
tive women (Lizarraga et al. 2010). The study controlled 
for race and tumor size, but did not examine the poten-
tial interaction between race and biologic subtype. Given 
the difference in incidence of biologic subtype between 
black and white women, as well as the potential disparity 
in type of surgery in black and white women presenting 
with early stage breast cancer, this study aimed to exam-
ine the odds of mastectomy compared to lumpectomy by 
molecular subtype in black and white women with size 
T1 and T2 invasive breast cancer.
Methods
This study used the National Cancer Institute’s Surveil-
lance, Epidemiology and End Results (SEER) 18 regions 
research database. Women between the ages of 15 and 
85+ years diagnosed with T1 or T2 invasive breast can-
cer between the years 2010 and 2012 were included in the 
sample. During these years in the SEER database, Her2 
status was routinely recorded for all invasive breast can-
cers and anti-Her2 therapy was considered standard of 
care for patients with Her2 positive disease. For women 
with multiple tumors over their lifespan, only the first 
primary tumor was included in the analysis. Women 
whose first primary tumor was not invasive breast can-
cer, with a primary tumor diagnosed prior to 2010 and 
those without complete information on hormone recep-
tor (HR)—which includes ER and PR—and Her2 status 
were excluded.
Tumors were categorized as the following: Her2+/
HR+, Her2+/HR−, Her2−/HR+ and Her2−/HR− using 
the breast subtype variable available in the SEER database 
(Howlader et al. 2014). Data were stratified by tumor size 
(T1 or T2) and race. Bivariate comparisons were made 
using Chi square (χ2) and logistic regression models 
adjusted for age were used to determine the odds of mas-
tectomy by breast cancer molecular subtype. All analyses 
were conducted using SAS 9.3 (Cary, NC).
Results
The final sample included 112,963 women who were diag-
nosed with a T1 or T2 invasive breast cancer between 
2010 and 2012. Demographic information for the sample 
stratified by surgery type is outlined in Table 1. Overall, 
women who underwent a mastectomy were more likely 
to be younger, have a T2 tumor and be of a race other 
than white.
Results of the stratified regression models are reported 
in Table 2. For women with T1 tumors, there was a sta-
tistically significant interaction between tumor subtype 
and race (χ2 = 21.2, p = 0.002). For this reason, in women 
with T1 tumors, the results are stratified by race. There 
was not a statistically significant interaction between 
tumor subtype and race in T2 tumors (χ2 = 8.9, p = 0.18) 
and the results are presented for all races combined.
T1 tumors
For white women with T1 tumors, the odds of mastec-
tomy differed based on biologic subtype. When white 
women with the same Her2 status were compared 
according to differing HR status, those with HR nega-
tive tumors were more likely to undergo a mastectomy 
than those with HR positive tumors (Her2+/HR+  vs 
Her2+/HR− OR  =  0.63, 95  % CI 0.57, 0.70; Her2−/
HR+  vs Her2−/HR− OR  =  0.83, 95  % CI 0.78, 0.88). 
Table 1 Demographic characteristics stratified by  surgery 
type (N = 112,963)
Lumpectomy N (%) Mastectomy N (%) p
Age
 15–49 11,532 (17) 13,011 (29) <0.0001
 50–85+ 56,607 (83) 31,813 (71)
Race
 White 55,666 (82) 35,341 (79) <0.0001
 Black 6865 (10) 4,683 (10)
 Other 5,608 (8) 4,800 (11)
Tumor size
 T1 51,079 (75) 24,200 (54) <0.0001
 T2 17,060 (25) 20,624 (46)
Biologic subtype
 HR+/Her2+ 5,775 (8) 5,294 (12) <0.0001
 HR−/Her2+ 2,008 (3) 2,500 (6)
 HR+/Her2- 53,214 (78) 31,604 (70)
 Triple negative 7,142 (10) 5,426 (12)
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When the Her2 status was different between compari-
son groups, white women with Her2+ tumors were more 
likely to undergo a mastectomy, regardless of HR status, 
although the strength of the association varied. The larg-
est association was seen with Her2+/HR− vs Her2−/
HR+ (OR = 2.28, 95 % CI 2.08, 2.50), followed by Her2+/
HR− vs Her2−/HR− (OR 1.20, 95 % CI 1.10, 1.30).
Black women with T1 tumors had a similar, though 
not identical, pattern. However, the magnitude of asso-
ciations is smaller between most biologic subtypes com-
pared to white women and women of other races. In 
black women with T1 tumors, when Her2 status is the 
same between comparison groups, there is no statistically 
significant difference in odds of mastectomy, regardless 
of HR status (Her2+/HR+  vs Her2+/HR− OR =  0.86, 
95 % CI 0.65, 1.13; Her2−/HR+ vs Her2−/HR− OR 1.09, 
95 % CI 0.95, 1.26). When comparing those with differing 
Her2 status, black women with Her2+ tumors were more 
likely to undergo a mastectomy (Her2+/HR− vs Her2−/
HR− OR  =  1.65, 95  % CI 1.27, 2.14; Her2+/HR− vs 
Her2−/HR+ OR 1.51, 95 % CI 1.19, 1.91; Her2+/HR+ vs 
Her2−/HR− OR  =  1.42, 95  % CI 1.16, 1.72; Her2+/
HR+ vs Her2−/HR+ OR = 1.30, 95 % CI 1.10, 1.52).
When comparing women of other races with T1 
tumors and positive Her2 status, those with HR negative 
tumors were more likely to undergo a mastectomy than 
those with HR positive tumors (Her2+/HR+ vs Her2+/
HR− OR  =  0.61, 95  % CI 0.47, 0.80). However, when 
Her2 status is negative, there is no statistically significant 
difference in odds of mastectomy by differing HR status 
(Her2−/HR+  vs Her2−/HR− OR 0.85, 95  % CI 0.69, 
1.04). When comparing those with differing Her2 status, 
women with Her2 positive tumors were more likely to 
undergo a mastectomy (Her2+/HR− vs Her2−/HR− OR 
1.84, 95 % CI 1.37, 2.47; Her2+/HR− vs Her2−/HR+ OR 
2.17, 95 % CI 1.72, 2.74; Her2+/HR+ vs Her2−/HR+ OR 
1.33, 95  % CI 1.12, 1.57), with the exception of the 
Her2+/HR+ vs Her2−/HR− comparison, which was not 
statistically significant (OR = 1.12, 95 % CI 0.88, 1.44).
T2 tumors
There was no statistically significant interaction between 
tumor subtype and race in T2 tumors. For all races com-
bined, when comparing groups with the same Her2 status 
but differing HR status, women with HR positive tumors 
were less likely to undergo a mastectomy than those with 
HR negative tumors (Her2+/HR+  vs Her2+/HR− OR 
0.66, 95  % CI 0.60, 0.72; Her2−/HR+  vs Her2−/HR− 
OR = 0.86, 95 % CI 0.82, 0.91). When comparing groups 
with differing Her2 status, women with Her2 positive 
tumors were more likely to undergo a mastectomy than 
those with Her2 negative tumors, although the magni-
tude varied. The largest association was seen between 
Her2+/HR− vs Her2−/HR+  tumors (OR =  2.16, 95  % 
CI 1.99, 2.34), followed by Her2+/HR− vs Her2−/HR− 
(OR 1.87, 95  % CI 1.70, 2.05), Her2+/HR+  vs Her2−/
HR+ (OR = 1.42, 95 % CI 1.34, 1.50) and Her2+/HR+ vs 
Her2−/HR− (OR = 1.22, 95 % CI 1.14, 1.32).
Discussion
The results of this study suggest that HR status and Her2 
status may influence mastectomy rates in women with 
T1 and T2 tumors who were diagnosed between 2010 
and 2012. These women were diagnosed after the use of 
anti-Her2 therapy became standard of care in women 
with Her2 positive disease. In T1 tumors, the odds ratios 
of mastectomy to lumpectomy black women are smaller 
than those for white women and women of other races. 
The direction of the relationship is the same, however, 
the effect sizes for the odds of mastectomy are different 
with the largest discrepancy being for the comparison 
of Her2+/HR− and Her2−/HR+ tumors. Even with the 
differences across races in T1 tumors, general patterns 
can be seen in surgical decision-making across races 
and tumor size. In general, when Her2 status is the same 
between comparison groups, positive HR status is asso-
ciated with a reduced odds of undergoing a mastectomy. 
More interestingly, when Her2 status is different between 
Table 2 Age-adjusted odds ratios of mastectomy to lumpectomy between breast cancer biologic subtypes for T1 tumors 
stratified by race and T2 tumors
T1 White Black Other T2 OR (95 % CI)
OR (95 % CI) OR (95 % CI) OR (95 % CI)
Her2+/HR+ vs Her2+/HR− 0.63 (0.57, 0.70) 0.86 (0.65, 1.13) 0.61 (0.47, 0.80) Her2+/HR+ vs Her2+/HR− 0.66 (0.60, 0.72)
Her2+/HR+ vs Her2−/HR+ 1.44 (1.36, 1.53) 1.30 (1.10, 1.52) 1.33 (1.12, 1.57) Her2+/HR+ vs Her2−/HR+ 1.42 (1.34, 1.50)
Her2+/HR+ vs triple negative 1.20 (1.10, 1.30) 1.42 (1.16, 1.72) 1.12 (0.88, 1.44) Her2+/HR+ vs triple negative 1.22 (1.14, 1.32)
Her2+/HR− vs Her2−/HR+ 2.28 (2.08, 2.50) 1.51 (1.19, 1.91) 2.17 (1.72, 2.74) Her2+/HR− vs Her2−/HR+ 2.16 (1.99, 2.34)
Her2+/HR− vs triple negative 1.89 (1.69, 2.10) 1.65 (1.27, 2.14) 1.84 (1.37, 2.47) Her2+/HR− vs triple negative 1.87 (1.70, 2.05)
Her2−/HR+ vs triple negative 0.83 (0.78, 0.88) 1.09 (0.95, 1.26) 0.85 (0.69, 1.04) Her2−/HR+ vs triple negative 0.86 (0.82, 0.91)
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comparison groups, Her2 positivity is associated with an 
increased odds of undergoing a mastectomy.
There is limited, and conflicting, data on the relation-
ship between Her2 status and the risk of locoregional 
recurrence. Nguyen and colleagues previously reported a 
higher rate of local recurrence in Her2 positive patients 
compared to HR positive/Her2 negative patients 
(adjusted hazard ratio = 9.2, 95 % CI 1.6, 51; p = 0.012); 
however, none of the patients in this 2008 study received 
anti-Her2 therapy, which has become standard of care in 
patients with Her2 positive disease (Nguyen et al. 2008). 
It has been well-established that the use of adjuvant anti-
Her2 therapy in the treatment of Her2 positive tumors 
reduces the risk of both local recurrence as well as dis-
tant metastasis (Piccart-Gebhart et  al. 2005; Romond 
et  al. 2005). Therefore, it is unknown if a higher recur-
rence rate would be realized if these women had received 
modern anti-Her2 regimens. Without definitive evidence 
of higher locoregional or distant metastasis in women 
with early stage breast cancer, the reasoning behind 
higher mastectomy rates in Her2 positive disease remains 
unclear.
There are limitations to this study. First, we excluded 
women with missing HR or Her2 status. The overall sam-
ple had 2.6 % missing ER status, 3.1 % missing PR status 
and 7.1  % missing Her2 status. The missing data were 
not randomly distributed across age, race, SEER registry 
or tumor size. It is unclear how much the missing data 
may bias results or the direction of any potential bias and 
may lead to a differential under-or over-estimation of the 
association between biologic subtypes and mastectomy 
rates. Second, neither multifocality nor multicentricity 
is a documented variable in the SEER database. Using 
T-stage only, without knowledge of the possibility of mul-
tifocality or multicentricity, may grossly underestimate 
the extent of disease within the breast. This may have 
been a confounding factor in a woman’s surgical deci-
sion-making process. Third, there is no information in 
the SEER database regarding family history of malignan-
cies. Although this should be evenly distributed across all 
molecular subtypes, it is impossible to know if a signifi-
cant family history of cancer may have contributed to the 
decision to proceed with a mastectomy.
The phenomenon of increasing mastectomy rates in 
early stage breast cancer has been well described. In an 
analysis of the National Cancer Database, Kummerow 
et al. reported a 37.8 % mastectomy rate in 2011 in women 
with early stage breast cancer (2015). These results are 
consistent with other long term studies investigating the 
use mastectomy over breast-conserving surgery (Dragun 
et al. 2013; McGuire et al. 2009). With this trend in mind, 
it is even more imperative that differences in mastectomy 
rates be continuously investigated. There are no guidelines 
or evidence based recommendations suggesting that sur-
gical decision-making should be based on tumor biol-
ogy. The underlying knowledge that Her2 positive disease 
tends to be a more aggressive phenotype may lead both 
patients and physicians to falsely believe breast-conserv-
ing surgery to be unsafe, despite no evidence to suggest 
that this is the case. The strong association between Her2 
positive disease and mastectomy rates described in this 
study suggests that further investigation is needed into 
how information about the diagnosed cancer and the pos-
sible surgical options are presented to a patient. Identify-
ing the factors involved in the surgical decision-making 
process is necessary to ensure all information provided to 
patients is evidence based, rather than perception based. 
A better understanding of the delivery of information may 
shed some light on the observed differences in mastec-
tomy rates based on tumor subtype.
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